21 – 30 of 37
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
Selective targeting of primary and secondary nucleation pathways in Ab42 aggregation using a rational antibody scanning method
(
- Contribution to journal › Article
-
Mark
Monomeric and fibrillar α-synuclein exert opposite effects on the catalytic cycle that promotes the proliferation of Aβ42 aggregates
2017) In Proceedings of the National Academy of Sciences of the United States of America 114(30). p.8005-8010(
- Contribution to journal › Article
-
Mark
Phage display and kinetic selection of antibodies that specifically inhibit amyloid self-replication
2017) In Proceedings of the National Academy of Sciences of the United States of America 114(25). p.6444-6449(
- Contribution to journal › Article
-
Mark
Scaling behaviour and rate-determining steps in filamentous self-assembly
(
- Contribution to journal › Article
-
Mark
Systematic development of small molecules to inhibit specific microscopic steps of Aβ42 aggregation in Alzheimer's disease
2017) In Proceedings of the National Academy of Sciences of the United States of America 114(2). p.200-208(
- Contribution to journal › Article
- 2016
-
Mark
Structural Insights into the Calcium-Mediated Allosteric Transition in the C-Terminal Domain of Calmodulin from Nuclear Magnetic Resonance Measurements.
(
- Contribution to journal › Article
-
Mark
Chemical properties of lipids strongly affect the kinetics of the membrane-induced aggregation of α-synuclein
2016) In Proceedings of the National Academy of Sciences of the United States of America 113(26). p.7065-7070(
- Contribution to journal › Article
-
Mark
Molecular mechanisms of protein aggregation from global fitting of kinetic models.
(
- Contribution to journal › Article
-
Mark
Kinetic analysis reveals the diversity of microscopic mechanisms through which molecular chaperones suppress amyloid formation
(
- Contribution to journal › Article
-
Mark
An anticancer drug suppresses the primary nucleation reaction that initiates the production of the toxic Aβ42 aggregates linked with Alzheimer's disease.
(
- Contribution to journal › Article